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ABSTRACT
Dominant-negative mutations in the homopentameric extracellular matrix glycoprotein cartilage oligomeric matrix protein
(COMP) result in inappropriate intracellular retention of misfolded COMP in the rough endoplasmic reticulum of chondrocytes,
causing chondrocyte cell death, which leads to two skeletal dysplasias: pseudoachondroplasia (PSACH) and multiple epiphyseal
dysplasia (EDM1). COMP null mice show no adverse effects on normal bone development and growth, suggesting a possible
therapy involving removal of COMP mRNA. The goal of this study was to assess the ability of a hammerhead ribozyme (Ribo56,
designed against the D469del mutation) to reduce COMP mRNA expression. In COS7 cells transfected with plasmids that
overexpress wild-type or mutant COMP mRNA and Ribo56, the ribozyme reduced overexpressed normal COMP mRNA by 46%
and mutant COMP mRNA by 56% in a dose-dependent manner. Surprisingly, the use of recombinant adenoviruses to deliver
wild-type or mutant COMP mRNA and Ribo56 simultaneously into COS7 cells proved problematic for the activity of the
ribozyme to reduce COMP expression. However, in normal human costochondral cells (hCCCs) infected only with adenoviruses
expressing Ribo56, expression of endogenous wild-type COMP mRNA was reduced in a dose-dependent manner by 50%. In
chondrocytes that contain heterozygous COMP mutations (D469del, G427E and D511Y) that cause PSACH, Ribo56 was more
effective at reducing COMP mRNA (up to 70%). These results indicate that Ribo56 is effective at reducing mutant and wild-type
COMP levels in cells and suggests a possible mode of therapy to reduce the mutant protein load.
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INTRODUCTION
Cartilage oligomeric matrix protein (COMP/TSP-5) is one
of the proteins that comprise the complex extracellular
matrix (ECM) networks of cartilage, tendon, and ligament
that cushion and stabilize skeletal elements (Kempson et al.
1968; Urban et al. 1979; Schmidt et al. 1990). COMP, the
fifth member of the thrombospondin (TSP) gene family, is
a multidomain homopentameric protein comprised of an
N-terminal pentamerization domain, an epidermal growth
factor (EGF)-like domain, a highly conserved type 3
(calcium-binding) repeat domain, and a C-terminal glob-
ular region (Fife and Brandt 1984; DiCesare et al. 1994;
Adams et al. 1995; Smith et al. 1997; Hecht et al. 1998a;
Carlson et al. 2008). Recent work suggests that COMP is
multifunctional and is involved in (1) regulation of
collagen fiber assembly/diameter (Rosenberg et al. 1998);
(2) interaction with other ECM molecules (Holden et al.
2001; Thur et al. 2001; Mann et al. 2004); (3) regulation of
chondrocyte proliferation (Kipnes et al. 2003; Xu et al.
2007); (4) regulation of apoptosis (Duke et al. 2003;
Hashimoto et al. 2003; Hecht et al. 2004); and (5)
enhancement of cellular attachment (Chen et al. 2005).
Mutations in COMP cause two skeletal dysplasias: a severe
disproportionate dwarfing condition, pseudoachondroplasia
(PSACH), and a milder condition, multiple epiphyseal
dysplasia (MED/EDM1 subtype) (Briggs et al. 1995; Hecht
et al. 1995; Thur et al. 2001; Briggs and Chapman 2002).
PSACH is a dwarfing condition in which infants have a
normal birth length and weight and are first diagnosed when
their linear growth decelerates between 1 and 2 years of age
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(Unger and Hecht 2001; Posey et al. 2004). Characteristic
PSACH clinical findings include waddling gait beginning in
early childhood; widened and lax joints; brachydactyly;
windswept, knock knee, or bowing deformities of the lower
extremities; exaggerated lumbar lordosis; and early onset
osteoarthritis (Unger and Hecht 2001; Posey et al. 2004).
Replacement of the weight-bearing joints, particularly knees
and hips, often is required in early adulthood (Unger and
Hecht 2001). In contrast to PSACH, MED is diagnosed
around five years of age when the children present with
abnormal gait and/or stiff painful hips (Unger and Hecht
2001). Mild short stature and osteonecrosis of the hips
(Legg-Perthes disease) are also frequent findings in MED
(Unger and Hecht 2001). Hip replacement often is needed in
early adulthood (Unger and Hecht 2001).
More than 100 novel COMP mutations have been
identified, with the majority found in the highly conserved
type 3 calcium-binding repeat domain (Briggs et al. 1995;
Hecht et al. 1995; Unger and Hecht 2001; Kennedy et al.
2005). The most common mutation, D469del, accounts for
z30% of all PSACH cases (Unger and Hecht 2001; Kennedy
et al. 2005). These mutations produce a COMP molecule
consisting of a mixture of mutant and wild-type subunits
that causes protein stalling in the rER and intracellular
COMP accumulation in large rER cisternae (Cooper et al.
1973; Hecht et al. 1998b, 2005; Chen et al. 2004). This
massive intracellular protein retention eventually leads to
chondrocyte death; the loss of chondrocytes translates into
markedly diminished linear growth in affected individuals
(Unger and Hecht 2001; Briggs and Chapman 2002).
Transgenic mouse models expressing mutant COMP
demonstrate a mild PSACH phenotype (Pirog-Garcia
et al. 2007; Schmitz et al. 2007; Posey et al. 2008). In
contrast, COMP knockout mice develop normally, suggest-
ing that COMP may not be necessary or has a redundant
function in cartilage formation, bone growth, and extra-
cellular cartilage matrix (ECM) development (Svensson
et al. 2002). These observations led to the hypothesis that
elimination of a majority of the mutant COMP from the
secretory pathway would prevent the cellular pathology
associated with the PSACH phenotype without side effects
owed to partial reduction of its normal counterpart. RNAi
(interference) technology is one approach that could be
used to reduce in vitro and in vivo gene expression.
Ribozymes are short catalytic RNA oligonucleotides that
either splice or cleave RNA molecules and were hailed in
the early years of gene therapy research for their potential
to control gene expression (Cameron and Jennings 1989;
Haseloff and Gerlach 1992; McCall et al. 1992; James and
Turner 1997). However, interest in ribozymes faded when
they did not reliably knock down targeted genes and with
the advent of siRNA technologies. Recently, there has been
a renewed interest in the use of ribozymes as a means to
knock down expression of specific genes because of recent
advances in design and delivery, better stabilization, and
their ability to remain active over long periods in vivo.
Hammerhead ribozymes are small ribozymes consisting of
24–35 nucleotides and three stem–loop structures that
induce a site-specific cleavage of RNA based on Watson–
Crick base pairing with their target sequences (Haseloff and
Gerlach 1988; Ruffner et al. 1990; Shimayama et al. 1995).
Because the hammerhead ribozyme functional sequence is
short and conserved, novel designs can quickly be synthe-
sized and tested in cell culture for knockdown of mRNA
expression of genes that cause disease (Hendry et al. 1997;
Tabler and Sczakiel 1997; Blount and Uhlenbeck 2002; Liu
et al. 2002; Khan 2006). In addition, ribozymes, unlike
siRNA, are not thought to activate interferon responses
(Shiota et al. 2004), so they may have longer-term utility in
whole animal/humans. These studies were undertaken to
test the efficacy and potential utility in gene therapy
applications of a novel ribozyme targeting COMP.
RESULTS
COMP-specific ribozyme (Ribo56) reduces
steady-state levels of wild-type COMP mRNA
or mutant COMP (D469del) mRNA and protein
in transfected COS7 cells
To determine whether Ribo56 can reduce steady-state wild-
type (WT) and mutant (MT) COMP mRNA in cells, COS7
cells were transfected with plasmids that express WT-COMP
(pWT-COMP) or MT-COMP (pMT-COMP). Since these
cells do not express COMP or other cartilage-specific ECM
proteins (Hashimoto et al. 2003), all of the WT and MT-
COMP mRNA assessed in these studies was expressed from
the plasmids. Cells were cotransfected with increasing
amounts (03–323) of a plasmid that express Ribo56
(pRibo56). Transfection efficiency in COS7 cells was consis-
tently found to be 30%–35% (data not shown). RNA and
protein were isolated 72-h post-transfection and subjected to
Northern andWestern analysis. Northern analysis of WT and
MT-COMP mRNA (shown in Fig. 1A) indicates that Ribo56
decreased steady-state levels of WT- and MT-COMP mRNA
in a dose-dependent manner. The reduction in mRNA
expression is significant (P < 0.05) for Ribo56 at concen-
trations of 8, 16, and 323 compared with RNA levels without
Ribo56 (Fig. 1A). The most efficient knockdown of COMP
mRNA occurred at 323 Ribo56, with 46% reduction of WT-
COMP mRNA and 56% reduction of MT-COMP mRNA
levels. Importantly, Ribo56 had comparable activity against
WT- and MT-COMP in this assay. Surprisingly, Ribo56
appeared to be more effective against MT-COMP (D469del)
mRNA thanWT-COMPmRNA, although the difference was
not significant (P = 0.16) in this assay.
Western analysis was performed to assess MT-COMP
protein knockdown by Ribo56 in the COS7 cells that were
transfected with pMT-COMP and pRibo56 at concentra-
tions 0 and 323. Protein was isolated 72-h post-transfection.
Ribozyme knockdown of COMP
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The results of three independent transfections are shown in
Figure 1B. Quantification of intracellular MT-COMP pro-
tein shows that, in the presence of Ribo56 at a concentration
of 323, COMP was significantly reduced by 45%. These
findings demonstrate that Ribo56 has the ability to reduce
COMP protein levels in COS7 cells by reducing the steady-
state levels of MT-COMP mRNA.
Dual adenovirus infection increases
steady-state levels of COMP mRNA
and protein in COS7 cells
The feasibility of a recombinant adeno-
virus system to deliver Ribo56 to cells
was assessed in COS7 cells. COS7 cells
were coinfected at a constant multiplicity
of infection (MOI) of a recombinant
adenovirus that expressed either WT-
COMP (AdWT) or MT-COMP (AdMT)
with an increasing MOI (0–323) of a
recombinant adenovirus expressing
Ribo56 (AdRibo56). Infected cells were
incubated for 96 h, and the RNA was
isolated. Northern analysis showed that
neither WT- nor MT-COMP mRNAs
decreased in the presence of increasing
Ribo56 in these cells (Fig. 2A). In fact,
steady-state COMP mRNA levels
increased with increasing MOI of
AdRibo56 (Fig. 2A). This increase also
was reflected in the steady-state levels of
WT- and MT-COMP protein (Fig. 2B).
Surprisingly, the coinfection unexpec-
tantly appeared to increase steady-state
levels of COMP mRNA and protein.
To assess whether the increase of
COMP mRNA was due to increased
Ribo56 or adenovirus, the experiment
was repeated using increasing AdGFP
with constant AdWT- or AdMT-COMP.
The results in Figure 3 show that the
expression of both WT- and MT-COMP
mRNA increases in the presence of an
increasing amount of AdGFP. These data
suggest that increasing adenovirus infec-
tion leads to activation of the CMV
promoter driving COMP expression.
Therefore, the dual infection approach
for disease modeling was abandoned.
Expression of endogenous COMP
mRNA is decreased in a dose-
dependent manner in primary human
chondrocytes (hCCCs) infected with
increasing MOIs of AdRibo56
Previous experiments suggested that adenoviral delivery of
genes to hCCCs can be efficiently undertaken (Merritt et al.
2006). However, the coinfection results described above
suggest that in the presence of two different adenoviruses,
one encoding the target and one encoding the ribozyme,
there are unexpected interactions that lead to an overall
increase in the levels of COMP (Fig. 2). To determine
FIGURE 1. WT- and MT-COMP expression is decreased in a dose-dependent manner in
COS7 cells cotransfected with increasing amounts of Ribo56 plasmid. COS7 cells were
cotransfected with 250 ng of either pWT-COMP or pMT-COMP and increasing amounts of
pRibo56. RNA and cellular protein were harvested 72 h after transfection. (A) Total RNA (7
mg) was subjected to Northern analysis using radiolabeled probes specific for COMP and
human GAPDH (loading control). Representative autoradiographs (N = 6) are shown above,
while normalization of COMP mRNA knockdown is displayed in the bar graph. COS7 cells
expressing only COMP (03) were normalized to 1. Error bars represent the standard error of
sample means (SEM), and P < 0.05 was considered significant (*). (B) Protein (30 mg) was
subjected to Western analysis of three independent experiments with pMT-COMP using
antibodies specific for COMP and b-actin (loading control). Shown are the resulting
autoradiographs and bar graph normalization of the results.
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whether this was an artifact of cotransfection of two viral
expression vectors, studies were undertaken to investigate
the knockdown of endogenous COMP in hCCCs. The
hCCCs were infected with increasing MOIs of AdRibo56
ranging from 0 to 200. RNA was isolated 96-h post-infection
and subjected to Northern analysis. As shown in Figure 4,
FIGURE 2. Adenovirus-based COMP expression is increased in a dose-dependent manner in COS7 cells when coinfected with adenovirus
expressing Ribo56. COS7 cells were coinfected with either AdWT- or AdMT-COMP with an increasing MOI of AdRibo56. RNA and cellular
proteins were collected after 96 h. (A) Total RNA (7 mg) was subjected to Northern analysis using radiolabeled probes specific for COMP and
human GAPDH (loading control). Resulting autoradiographs are shown above, while normalization of COMP mRNA knockdown is displayed in
the bar graph. COS7 cells expressing only COMP (03) were normalized to 1. (B) Protein (30 mg) was subjected to Western analysis using
antibodies specific for COMP and b-actin (loading control). Shown are the resulting autoradiographs and normalized data.
Ribozyme knockdown of COMP
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the presence of AdRibo56 significantly (P < 0.05) decreased
endogenous steady-state normal COMP mRNA levels in the
hCCCs at the highest MOIs. As the AdRibo56 MOI
increased to 100, dose-dependent knockdown was observed;
endogenous COMP mRNA expression was reduced by 47%
for AdRibo56 at an MOI of 100.
AdRibo56 reduces COMP mRNA expression
in primary mutant PSACH chondrocytes with
three different COMP mutations more efficiently
than in normal chondrocytes
Results shown in Figure 4 indicated that the adenovirus
delivery system can be used to knock down endogenous
WT-COMP in primary hCCCs. The next series of experi-
ments were performed to determine whether AdRibo56
reduces COMP mRNA levels in three primary PSACH
chondrocytes with G427E, D469del, or D511Y COMP
mutations and to compare the extent of knockdown to
that of the normal COMP. Mutant chondrocytes were
infected with AdRibo56 at MOIs of 0, 50, 75, and 100. As
seen in Figure 5, Northern analysis of mRNA from these
cells shows a reduction in the steady-state COMP with
increasing MOIs of AdRibo56 for all PSACH mutations.
Quantification shows that at all MOIs greater than 50,
AdRibo56 significantly reduced the WT- and to a greater
extent the MT-COMP mRNA levels. The D469del mRNA
was maximally reduced by 73% at an MOI of 75, the G427
and D511Y mRNAs were maximally reduced by 70% and
77%, respectively, at an MOI of 100. These results indicate
that Ribo56 is very effective at reducing steady-state levels
of MT-COMP for all three mutations but specifically
appears more effective against D469del MT-COMP at
lower MOIs. These data indicate that Ribo56 is more
effective against MT-COMP compared with endogenous
WT-COMP when expressed in chondrocytes (Fig. 5).
DISCUSSION
This is the first report to show reduction of COMP using a
ribozyme that is amenable to use in future gene therapy
applications for patients suffering from COMP-related
skeletal dysplasias. Ribo56, a hammerhead ribozyme
directed against the COMP sequence, targets the GUC
triplet near nucleotide 56 of the mature mRNA and
successfully reduces protein levels of both WT- and MT-
COMP in chondrocytes. Most importantly, the ribozyme is
more active in knockdown of three well-described MT-
COMP species in chondrocytes when compared with
normal WT-COMP (Fig. 4). Such preference presumably
occurs because of differences in the secondary structure
(Andronescu et al. 2005) or accessibility of target sequences
in ribonucleoprotein complexes (Welting et al. 2008) of the
transcripts encoding wild-type versus mutant COMP.
Selective targeting of mutant COMP over WT-COMP by
a ribozyme has never been reported.
In the initial phases of this study, COS7 cells were used as
an in vitro model because the cells are easily transfected
and, importantly, they do not synthesize COMP or any
other ECM protein that might potentially interfere with the
outcome (Hashimoto et al. 2003). Therefore, these studies
directly tested the ability of Ribo56 to knock down either
WT- or MT-COMP mRNA and protein without competi-
tion from endogenous COMP. Transfected cells can take
up more than one type of plasmid efficiently, eliminating
the possibility of singly transfected cells and allowing dose-
dependent assessment of the ribozyme. The results clearly
demonstrate that Ribo56 significantly reduced COMP
mRNA at most concentrations (83–323) but was most
effective at the highest concentration (323). Under these
conditions, when both target and ribozyme were expressed
from a plasmid, Ribo56 reduced WT- or MT-COMP
equally. In these studies, MT-COMP mRNA was reduced
by at least 50% and protein levels by 45%. These results
indicate that COMP mRNA knockdown is reflected in the
reduction of COMP protein levels in this model system.
FIGURE 3. Adenovirus-based COMP expression is increased in
COS7 cells when coinfected with adenovirus expressing only GFP.
COS7 cells were coinfected with either AdWT- or AdMT-COMP with
an increasing MOI of AdGFP. Cellular proteins were collected after
96 h. (A) Protein (30 mg) from AdWT-COMP:AdGFP was subjected
to Western analysis using antibodies specific for FLAG and b-actin
(loading control) and visualized by ECL. Resulting autoradiographs
are shown. (B) Normalized COMP protein from AdWT- or MT-
COMP:AdGFP is shown in the bar graph. COS7 cells expressing only
COMP (03) were normalized to 1.
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Recombinant adenovirus has been used to successfully
transfect a wide variety of primary and transformed cells
and hCCCs, in particular (Wickham et al. 1996; Merritt
et al. 2006). Therefore, recombinant adenovirus technology
was used to deliver AdRibo56 in the next series of studies.
Coinfection of WT- and MT-COMP into COS7 cells in the
presence of Ribo56 first was performed to assess the
effectiveness of adenovirally delivered ribozyme against
overexpressed COMP (James and Turner 1997; Tabler
and Sczakiel 1997; Merritt et al. 2006) in these cells.
Surprisingly, coinfection resulted in a net increase of both
WT- and MT-COMP mRNA and protein. This increase in
steady-state levels of COMP could be the result of inter-
actions of gene products of the two independent adenovi-
ruses that alter transcript processing, export, or stability or
increase gene expression in unanticipated ways (Timpe
et al. 2006). Alternatively, Ribo56 is not able to recognize or
cleave the target sequence when both are expressed from an
adenovirus. Interestingly, when the COMP adenovirus
MOI was reduced even further, the increase in steady-state
levels of COMP still occurred in the presence of the
ribozyme but only when it was delivered using an adeno-
viral vector (data not shown). This finding may suggest that
cellular stress from the presence of two separate adenoviral
vectors may stimulate COMP expression.
The disease pathology in PSACH is specific for the
growth plate chondrocytes (Cooper et al. 1973; Hecht
et al. 1998b; Hecht et al. 2004, 2005). Therefore, a system
with the capacity to deliver the ribozyme sequence into
these cells must be obtained. To eliminate the complica-
tions of synergistic effects on ribozyme activity from two
different adenoviruses and to test the function of Ribo56 in
a more native system, hCCCs were infected with different
MOIs of adRibo56 to determine the effect of the ribozyme
on endogenous COMP. As seen in Figure 3, steady-state
WT-COMP mRNA levels were reduced by Ribo56 in a
dose-dependent manner up to 50% at the highest concen-
trations. The same approach was used to test the effective-
ness of Ribo56 against MT-COMP in three different
PSACH patient hCCCs. The results shown in Figure 4
clearly show that COMP mRNA expression was reduced by
z70% for D468del, G427E, and D511Y mutations. The
magnitude of the reduction suggests that this ribozyme
may be more effective against MT-COMP than WT-COMP
in native chondrocytes. The difference in efficiency of
mRNA cleavage may be related to the difference in folding
patterns of the WT-COMP mRNA compared with the MT-
COMP (Fedor and Uhlenbeck 1990; Liu et al. 2000; Liu
et al. 2002). Even though the site of cleavage of Ribo56 is
near the 59 end of the COMP transcript, the changes in the
secondary structures of MT-COMP compared with WT-
COMP assessed by S-fold extend to the region comple-
mentary to the annealing arms of the ribozyme. Of interest,
the preference of the ribozyme for the mutant transcript
over the native one may selectively reduce the levels of the
mutant rather than the native form of COMP when both
coexist in PSACH chondrocytes (Merritt et al. 2006).
Mutations in COMP cause the PSACH and MED
(EMD1 type) skeletal dysplasias. The disease pathology of
these conditions results from the massive retention of
misfolded COMP and inappropriate formation of intracel-
lular matrix in the rER (Merritt et al. 2007). In contrast,
COMP null mice are normal, suggesting that loss of COMP
does not compromise normal growth, development, or
longevity. Thus, a treatment strategy removing or reducing
steady-state levels of mutant COMP in chondrocytes of
affected individuals is needed. Here, we show that Ribo56
can reduce COMP mRNA and protein with a preference for
knocking down the mutant form. This opens the door for
the use of mutant-recognizing ribozymes as an effective
gene therapy for these skeletal dysplasias.
MATERIALS AND METHODS
Cell culture
Cells (hCCCs) were obtained from patients undergoing pectus
excavatum surgery after informed consent at Shriners Hospital
for Children-Houston (Hecht et al. 1998b, 2004). hCCCs were
cultured as described above in 20% fetal bovine serum (FBS).
FIGURE 4. Expression of MT-COMP mRNA is decreased in a dose-
dependent manner in primary hCCCs infected with increasing MOIs
of adenovirus expressing Ribo56. Normal costochondral chondrocytes
were isolated as previously described and were transfected in mono-
layer with an increasing MOI of AdRibo56 (shown above the gel).
RNA was collected after 96 h. Total RNA (7 mg) was subjected to
Northern analysis using radiolabeled probes specific for COMP and
human GAPDH (loading control). Representative autoradiographs
(N = 5) are shown above, and COMP expression in uninfected cells
was used to normalize to 1. Error bars represent the SEM, and P <
0.05 was considered significant (*).
Ribozyme knockdown of COMP
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Two PSACH patient chondrocyte lines, D469del (deletion of
aspartic acid 469) and G427E, were obtained from the Iowa
skeletal dysplasia cell bank (Hecht et al. 1998b). The third
PSACH patient cell line, D511Y, was obtained from a growth
plate biopsy (Hecht et al. 2005). All of the chondrocyte samples
were from prepubertal children. These three PSACH cell lines
were heterozygous for the COMP mutations. Normal growth
plate chondrocytes were isolated as previously described (Hecht
et al. 2004).
Hammerhead ribozyme vectors
The hammerhead ribozyme (Ribo56) and annealing arms were
designed using the methods previously described (Liu et al. 2002) and
its target sequence validated using S-ribo (http://sfold.wadsworth.
org/sribo.pl). S-fold was used to compare the predicted secondary
structures for normal and three mutant COMP sequences chosen
for this study, all of which affected the predicted folding pattern of
the target transcripts in a manner that could impact interactions
with targeted ribozymes. Ribozyme 56 cuts at nucleotide 56 of the
COMP mRNA: 59-CUGCCCUCGGCGCGUCCGGACAGGGCC
AG-39. The cut site (underlined) lies in the region of the transcript
encoding the C-terminal half of the signal sequence extending just
into the coding sequence for the mature protein. Hence, blockade
or cleavage of this region will reduce transcript levels when cut
and interfere with translation of the key portion of the molecule
governing entry into the secretory pathway when functioning as
an antisense molecule. DNA encoding the hammerhead ribozyme
first was ligated into the BLOCK-iT U6 RNAi entry vector of the
ViraPower Lentiviral Gateway expression system (Invitrogen). The
Ribo56 construct includes a U6 promoter sequence, the small
nuclear RNA (snRNA) U1 sequence for stabilization of the
ribozyme and a Pol III termination sequence. To generate the
AdRibo56, the expression cassette was excised from the original
vector and ligated into the multiple cloning site of the pAdTrack-
GFP shuttle vector (Qbiogene). AdRibo56 was expanded to
working titers by Vector Biolabs.
Two COMP expression plasmid vectors were provided by Dr.
Jeff W. Stevens (University of Iowa) (Chen et al. 2004). These pc-
DNA3.1+ vectors contain either a WT-COMP (GenBank acces-
sion number: L32137) or MT-COMP (D469del) that have a FLAG
tag amino acid sequence (DYKDDDDK) added to the carboxyl
terminus. The recombinant adenoviruses (AdWT and AdMT)
were constructed as previously described (Merritt et al. 2006) and
expanded to working titers by Vector Biolabs.
Plasmid transfection
COS7 cells were cultured in 6-well tissue culture dishes and grown
to 80%–90% confluency. Cells were transfected per manufac-
turer’s instructions with plasmid DNA using a 3:2 ratio of
FuGene6 (Roche) to plasmid DNA. All transfections contained
250 ng of WT- or MT-COMP plasmid and were cotransfected
with varying amounts of Ribo56 and pUC18 plasmids for a total
of 8.25 mg DNA per transfection to obtain steady-state COMP
plasmid with an increasing concentration of Ribo56 plasmid
(Table 1). The COS7 cells were transfected and incubated for 96
h. The cells were collected at 96 h using either Trizol (Invitrogen)
for RNA or, for protein, RIPA buffer (50 mM Tris at pH 7.4, 150
mM NaCl, 2 mM EDTA, 1% [v/v] Triton X-100, Mini complete
protease inhibitors [Roche]; 1% [v/v] Na-deoxycholate; 0.1%
[v/v] SDS).
Viral transfection
The hCCCs were cultured in monolayer in T25 flasks and infected
for 18 h in serum-free Dulbecco’s modified Eagle medium
(DMEM) with AdRibo56 at MOIs of 0, 50, 75, 85, 95, 100, 110,
150, and 200. PSACH patient chondrocytes were infected using
MOIs of 0, 50, 75, and 100. The medium was replaced with
DMEM + 20% FBS and 1% Ab/Am and cells were incubated at
37°C for a total of 96 h. COS7 cells were cultured in 6-well tissue
culture dishes and grown to confluency. Cells then were infected
for 18 h using 1.5 mL of serum-free DMEM containing either
AdWT- or AdMT-COMP at an MOI of 1 and AdR56 with
FIGURE 5. COMP mRNA expression is decreased in a dose-
dependent manner in primary PSACH chondrocytes with three
different COMP mutations infected with increasing MOIs of adeno-
virus expressing Ribo56. PSACH chondrocytes heterozygous for WT
COMP and one of three COMP mutations (D469del, G427E, or
D511Y) were isolated as previously described and were infected with
increasing MOIs of AdRibo56. RNA was collected after 96 h. Total
RNA (7 mg) was subjected to Northern analysis using radiolabeled
probes specific for COMP and human GAPDH (loading control).
Representative autoradiographs (N = 3) are shown above, while
normalization of COMP mRNA knockdown is displayed in the bar
graph. COMP expression in uninfected cells (03) was normalized to
1. Error bars represent the SEM, and P < 0.05 was considered
significant. (*) P # 0.01 versus wild type; (#) P # 0.01 versus
D469del; (x) P # 0.01 versus G427E.
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increasing MOIs to give a ratio of 03 to 323. The medium was
replaced with DMEM + 10% FBS and 1% Ab/Am.
RNA isolation and purification from cultured cells
RNA was isolated from both plasmid and viral transfected COS7
cells and hCCCs after 72 or 96 h using 3 mL (for 6-well) or 4 mL
(T25 flask) of Trizol. The Trizol-cell mixture then was processed
using the PureLink Micro- to Midi-RNA isolation kit (Invitrogen)
following the manufacturer’s protocol. The RNA was quantitated
using a NanoDrop spectrophotomer (Thermo Fisher Scientific).
Purified samples were stored at 80°C.
Northern analysis
Northern analysis was performed as described in Sambrook and
Russell (2001). A radioactive probe was made using the Stratagene
Prime-It RmT Random primer labeling kit following the manu-
facturer’s protocol. The DNA templates were made from COMP
cDNA excised from a pcDNA3.1+ vector and gel purified using
theQiaquick gel extraction kit (Qiagen) following themanufacturer’s
protocol. Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
template obtained from Origene (GenBank: NM_002046) was excised
and gel purified as described above. The radioactive probe was
hybridized at 55°C overnight. The washed membrane was sealed
and exposed to X-ray film. Films were scanned and processed by
the software GeneSnap (Syngene) and analyzed for densitometry
using the GeneTools software (Syngene).
Protein isolation and Western analysis
Protein was isolated from transfected COS7 cells and chondro-
cytes by using 500 ml (for 6-well) or 1 mL (T25 flask) of RIPA
buffer. Western analysis was performed as described in Sambrook
and Russell (2001). Total protein (30 mg) was electrophoresed
through a NuPAGE 10% (w/v) Bis-Tris gel (Invitrogen). The gel
was transferred to a polyvinylidene fluoride (PVDF) membrane
(Millipore). The membrane was incubated with primary rabbit
(rab) polyclonal antibody for COMP (1:10,000) (Kamiya Bio-
medical) or the FLAG epitope (1:5,000) (Sigma Chemical Co) and
incubated with horseradish peroxidase (HRP) goat anti-rabbit IgG
(1:7,500) (GE Healthcare). To ensure uniform loading, b-actin
levels were determined with a b-actin rabbit primary conjugated
with HRP (1:75,000) (Abcam). Visualization of the complex was
accomplished using the ECL Plus kit (GE Healthcare) following
the manufacturer’s protocol. Films were scanned and processed
using GeneSnap (Syngene) and analyzed for densitometry using
GeneTools software (Syngene).
Statistical analysis
The results of each replicate experiment were compared for each
concentration of Ribo56 by dividing the pixel score of COMP by
the pixel score of GAPDH (RNA) or b-actin (protein) for the
corresponding lane (data not shown). A two-tailed t-test (P <
0.05) was used to assess the differences between the COMP mRNA
levels and the protein levels for the different experiments for each
concentration ratio by comparing them individually to the control
COMP levels. The control COMP mRNA levels and protein levels
were normalized to a density value of 1, and the mean value was
established in comparison for each Ribo56 concentration and
displayed in a bar graph. All error bars represent the standard
error of sample means (SEM). Asterisk (*) denotes mean values
that are significantly (P-value < 0.05) different from the control.
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